Displaying drugs 2376 - 2400 of 16161 in total
Levoketoconazole
Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.[A244078, A244083] Ketoconazole has been used both on- and off-label to treat...
Approved
Investigational
Matched Iupac: … 1-[4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl …
Matched Description: … chemistry, and opportunistic infections. ... chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and ... with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and …
Matched Categories: … Sex Hormones and Insulins …
Matched Description: … chemistry, and opportunistic infections. ... chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and ... with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and …
Matched Categories: … Sex Hormones and Insulins …
Ferrous cysteine glycinate
Approved
Matched Iupac: … lambda2-iron(2+) (2R)-2-amino-3-sulfanylpropanoic acid 2-aminoacetic acid (2R)-2-amino-3-sulfanidylpropanoate …
Olodaterol
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and...
Approved
Matched Description: … LABAs including improved convenience and compliance and improved airflow over a 24-hour period. ... novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and ... signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and …
Matched Categories: … olodaterol and tiotropium bromide …
Matched Categories: … olodaterol and tiotropium bromide …
Pipobroman
An antineoplastic agent that acts by alkylation.
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Eteplirsen
Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. It consists of a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and RNA. Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory...
Approved
Investigational
Matched Description: … Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. ... a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and ... Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Rabies virus inactivated antigen, B
Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.
Approved
Matched Description: … Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure …
Matched Categories: … Immune Sera and Immunoglobulins …
Matched Categories: … Immune Sera and Immunoglobulins …
Fremanezumab
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. ... [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and ... oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Diethylpropion
A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
Approved
Illicit
Matched Categories: … Alimentary Tract and Metabolism …
Dolichovespula maculata venom protein
Dolichovespula maculata venom protein is an extract of Dolichovespula maculata venom. Dolichovespula maculata venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Nefazodone
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with...
Approved
Withdrawn
Matched Categories: … Serotonin and Noradrenaline Reuptake Inhibitors ... Serotonin antagonist and reuptake inhibitors (SARIs) …
Cisapride
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Nimesulide
Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has...
Approved
Investigational
Withdrawn
Matched Description: … primary dysmenorrhoea in adolescents and adults above 12 years old. ... Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and ... Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Letrozole
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Approved
Investigational
Matched Iupac: … 4-[(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]benzonitrile …
Matched Description: … ], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Description: … ], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Darolutamide
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer...
Approved
Investigational
Matched Description: … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by ... darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents …
Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and...
Approved
Vet approved
Matched Iupac: … 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide …
Matched Description: … Meloxicam is available in oral, transdermal, and intravenous formulations. ... relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and …
Matched Categories: … bupivacaine and meloxicam ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Matched Description: … Meloxicam is available in oral, transdermal, and intravenous formulations. ... relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and …
Matched Categories: … bupivacaine and meloxicam ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Demecarium
Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase...
Approved
Matched Iupac: … N,N,N-trimethyl-3-{[methyl({10-[methyl({[3-(trimethylazaniumyl)phenoxy]carbonyl})amino]decyl})carbamoyl …
Matched Description: … Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. ... In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …
Matched Description: … Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. ... In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …
Plasma protein fraction (human)
The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma. It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. This biologic should come...
Approved
Matched Description: … [L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains ... some electrolytes such as sodium, potassium and chloride. ... protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Amprenavir
Amprenavir is a protease inhibitor used to treat HIV infection.
Approved
Investigational
Matched Categories: … Amprenavir and Prodrugs …
Choline C-11
Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.
Approved
Matched Iupac: … (2-hydroxyethyl)((11C)methyl)dimethylazanium …
Matched Description: … for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and …
Matched Description: … for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and …
Letermovir
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status...
Approved
Investigational
Matched Iupac: … -5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl]acetic acid …
Matched Description: … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. …
Matched Description: … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. …
Aurothioglucose
Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis.
Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s...
Approved
Withdrawn
Matched Description: … use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and ... Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and ... replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and …
Matched Categories: … Antiinflammatory and Antirheumatic Products …
Matched Categories: … Antiinflammatory and Antirheumatic Products …
Olive oil
Oil extracted from olives . Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Approved
Matched Description: … Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. ... Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products …
Matched Categories: … Diet, Food, and Nutrition …
Matched Categories: … Diet, Food, and Nutrition …
Anidulafungin
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
Approved
Investigational
Matched Description: … Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 2376 - 2400 of 16161 in total